You are here

Article info

Article menu
Immune cell therapies and immune cell engineering
Original research
Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy

Authors

  • Yalda Amidi Harvard Medical School, Boston, Massachusetts, USADepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USAClinical Data Animation Center (CDAC), Massachusetts General Hospital, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Christine A Eckhardt Harvard Medical School, Boston, Massachusetts, USADepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USAClinical Data Animation Center (CDAC), Massachusetts General Hospital, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Syed A Quadri Harvard Medical School, Boston, Massachusetts, USADepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USAClinical Data Animation Center (CDAC), Massachusetts General Hospital, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Preeti Malik Harvard Medical School, Boston, Massachusetts, USADepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USAClinical Data Animation Center (CDAC), Massachusetts General Hospital, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Marcos Santana Firme Harvard Medical School, Boston, Massachusetts, USADepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USAClinical Data Animation Center (CDAC), Massachusetts General Hospital, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Daniel K Jones Harvard Medical School, Boston, Massachusetts, USADepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USAClinical Data Animation Center (CDAC), Massachusetts General Hospital, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Aayushee Jain Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USAClinical Data Animation Center (CDAC), Massachusetts General Hospital, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Husain H Danish Harvard Medical School, Boston, Massachusetts, USADepartment of Neurology, Brigham and Women’s Hospital, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Daniel B Rubin Harvard Medical School, Boston, Massachusetts, USADepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USAClinical Data Animation Center (CDAC), Massachusetts General Hospital, Boston, MA, USACancer Center for Brain Health, Massachusetts General Hospital, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Caron A Jacobson Dana-Farber Cancer Institute, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Sydney S Cash Harvard Medical School, Boston, Massachusetts, USADepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USAClinical Data Animation Center (CDAC), Massachusetts General Hospital, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Jong Woo Lee Harvard Medical School, Boston, Massachusetts, USADepartment of Neurology, Brigham and Women’s Hospital, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Jorg Dietrich Harvard Medical School, Boston, Massachusetts, USADepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • M Brandon Westover Harvard Medical School, Boston, Massachusetts, USADepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USAClinical Data Animation Center (CDAC), Massachusetts General Hospital, Boston, MA, USACancer Center for Brain Health, Massachusetts General Hospital, Boston, MA, USA PubMed articlesGoogle scholar articles

Citation

Amidi Y, Eckhardt CA, Quadri SA, et al
Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy
Journal for ImmunoTherapy of Cancer 2022;10:e005459. doi: 10.1136/jitc-2022-005459
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.